Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 14837-14838 [2012-5998]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 49 / Tuesday, March 13, 2012 / Notices
Commission, Washington, DC 20555–
0001; telephone: 301–251–7404; or
email Richard.Jervey@nrc.gov.
SUPPLEMENTARY INFORMATION:
NUCLEAR REGULATORY
COMMISSION
[NRC–2012–0057]
Bioassay at Uranium Mills
Nuclear Regulatory
Commission.
ACTION: Draft regulatory guide; request
for comment.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC or the Commission)
is issuing for public comment draft
regulatory guide (DG), DG–8051,
‘‘Bioassay at Uranium Mills.’’ This
guide describes a bioassay program
acceptable to the NRC staff for uranium
mills and applicable portions of
uranium conversion facilities where the
possibility of exposure to yellowcake
dust exists, including exposure
conditions with and without the use of
respiratory protection devices.
DATES: Submit comments by May 11,
2012. Comments received after this date
will be considered if it is practical to do
so, but the NRC is able to ensure
consideration only for comments
received on or before this date.
Although a time limit is given,
comments and suggestions in
connection with items for inclusion in
guides currently being developed or
improvements in all published guides
are encouraged at any time.
ADDRESSES: You may access information
and comment submissions related to
this document, which the NRC
possesses and is publicly available, by
searching on https://www.regulations.gov
under Docket ID NRC–2012–0057. You
may submit comments by the following
methods:
• Federal Rulemaking Web site: Go to
https://www.regulations.gov and search
for Docket ID NRC–2012–0057. Address
questions about NRC dockets to Carol
Gallagher; telephone: 301–492–3668;
email: Carol.Gallagher@nrc.gov.
• Mail comments to: Cindy Bladey,
Chief, Rules, Announcements, and
Directives Branch (RADB), Office of
Administration, Mail Stop: TWB–05–
B01M, U.S. Nuclear Regulatory
Commission, Washington, DC 20555–
0001.
• Fax comments to: RADB at 301–
492–3446.
For additional direction on accessing
information and submitting comments,
see ‘‘Accessing Information and
Submitting Comments’’ in the
SUPPLEMENTARY INFORMATION section of
this document.
FOR FURTHER INFORMATION CONTACT: R.
A. Jervey, Office of Nuclear Regulatory
Research, U.S. Nuclear Regulatory
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
18:29 Mar 12, 2012
Jkt 226001
I. Accessing Information and
Submitting Comments
A. Accessing Information
Please refer to Docket ID NRC–2012–
0057 when contacting the NRC about
the availability of information regarding
this document. You may access
information related to this document,
which the NRC possesses and is
publicly available, by the following
methods:
• Federal Rulemaking Web Site: Go to
https://www.regulations.gov and search
for Docket ID NRC–2012–0057.
• NRC’s Agencywide Documents
Access and Management System
(ADAMS): You may access publicly
available documents online in the NRC
Library at https://www.nrc.gov/readingrm/adams.html. To begin the search,
select ‘‘ADAMS Public Documents’’ and
then select ‘‘Begin Web-based ADAMS
Search.’’ For problems with ADAMS,
please contact the NRC’s Public
Document Room (PDR) reference staff at
1–800–397–4209, 301–415–4737, or by
email to pdr.resource@nrc.gov. The draft
regulatory guide is available under
ADAMS accession No. ML110960333.
The regulatory analysis may be found in
ADAMS under accession No.
ML110960341.
Regulatory guides are not
copyrighted, and NRC approval is not
required to reproduce them.
II. Further Information
The NRC is issuing for public
comment a draft guide in the agency’s
‘‘Regulatory Guide’’ series. This series
was developed to describe and make
available to the public such information
as methods that are acceptable to the
NRC staff for implementing specific
parts of the NRC’s regulations,
techniques that the staff uses in
evaluating specific problems or
postulated accidents, and data that the
staff needs in its review of applications
for permits and licenses.
The draft regulatory guide, entitled,
‘‘Bioassay at Uranium Mills,’’ is
temporarily identified by its task
number, DG–8051, which should be
mentioned in all related
correspondence. DG–8051 is proposed
Revision 2 of Regulatory Guide 8.22,
previously revised in August 1988.
This guide is being updated to
incorporate changes made in 10 CFR
Part 20 since Regulatory Guide 8.22,
Revision 1 was issued. Comments
related to the operation of in-situ
PO 00000
Frm 00114
Fmt 4703
Sfmt 4703
14837
recovery mills and associated
considerations for bioassay are of
particular interest.
Dated at Rockville, Maryland, this 6th day
of March, 2012.
For the Nuclear Regulatory Commission.
Thomas H. Boyce,
Chief, Regulatory Guide Development Branch,
Division of Engineering, Office of Nuclear
Regulatory Research.
[FR Doc. 2012–6001 Filed 3–12–12; 8:45 am]
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
Advisory Committee on the Medical
Uses of Isotopes: Meeting Notice
U.S. Nuclear Regulatory
Commission.
ACTION: Notice of meeting.
AGENCY:
NRC will convene a meeting
of the Advisory Committee on the
Medical Uses of Isotopes (ACMUI) on
April 16–17, 2012. A sample of agenda
items to be discussed during the public
session includes: (1) Fundamental
concepts in patient advocacy; (2)
electronic signatures for documents that
are required to be signed in accordance
with U.S. Nuclear Regulatory
Commission (NRC) regulations; (3)
medical-related events from fiscal year
2011; (4) an update on proposed
regulatory changes for Permanent
Implant Brachytherapy programs; (5) the
status of the Commission Paper on data
collection for Patient Release; (6) a
status update on 10 CFR Part 35
rulemaking; (7) medical use of radium223 chloride; (8) an update on strontium
breakthrough with rubidium-82
generators from NRC and FDA
perspectives; and (9) half-life activity as
a function of solar activity. The agenda
is subject to change. The current agenda
and any updates will be available at
https://www.nrc.gov/reading-rm/doccollections/acmui/agenda or by
emailing Ms. Sophie Holiday at the
contact information below.
Purpose: Discuss issues related to 10
CFR Part 35 Medical Use of Byproduct
Material.
Date and Time for Closed Session:
April 16, 2012, from 8 a.m. to 10:45 a.m.
This session will be closed so that
ACMUI members can prepare for an
upcoming Commission briefing.
Date and Time for Open Sessions:
April 16, 2012, from 10:45 a.m. to 5 p.m.
and April 17, 2012, from 8 a.m. to 12:30
p.m.
Address for Public Meeting: U.S.
Nuclear Regulatory Commission, Two
White Flint North Building, Room T2–
SUMMARY:
E:\FR\FM\13MRN1.SGM
13MRN1
14838
Federal Register / Vol. 77, No. 49 / Tuesday, March 13, 2012 / Notices
B3, 11545 Rockville Pike, Rockville,
Maryland 20852.
Public Participation: Any member of
the public who wishes to participate in
the meeting in person or via phone
should contact Ms. Holiday using the
information below. The meeting will
also be webcast live: https://
www.nrc.gov/public-involve/publicmeetings/webcast-live.html.
Contact Information: Sophie J.
Holiday, email: sophie.holiday@nrc.gov,
telephone: (301) 415–7865.
Conduct of the Meeting
Leon S. Malmud, M.D., will chair the
meeting. Dr. Malmud will conduct the
meeting in a manner that will facilitate
the orderly conduct of business. The
following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a
written statement should submit an
electronic copy to Ms. Holiday at the
contact information listed above. All
submittals must be received by April 9,
2012, and must pertain to the topic on
the agenda for the meeting.
2. Questions and comments from
members of the public will be permitted
during the meeting, at the discretion of
the Chairman.
3. The draft transcript will be
available on ACMUI’s Web site (https://
www.nrc.gov/reading-rm/doccollections/acmui/tr/) on or about May
18, 2012. A meeting summary will be
available on ACMUI’s Web site (https://
www.nrc.gov/reading-rm/doccollections/acmui/meeting-summaries/)
on or about May 29, 2012.
4. Persons who require special
services, such as those for the hearing
impaired, should notify Ms. Holiday of
their planned attendance.
This meeting will be held in
accordance with the Atomic Energy Act
of 1954, as amended (primarily Section
161a); the Federal Advisory Committee
Act (5 U.S.C. App); and the
Commission’s regulations in Title 10,
U.S. Code of Federal Regulations, Part 7.
Dated: March 7, 2012.
Andrew L. Bates,
Advisory Committee Management Officer.
[FR Doc. 2012–5998 Filed 3–12–12; 8:45 am]
mstockstill on DSK4VPTVN1PROD with NOTICES
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
[NRC–2012–0002]
Sunshine Act Meeting
AGENCY HOLDING THE MEETINGS: Nuclear
Regulatory Commission, [NRC–2012–
0002].
VerDate Mar<15>2010
18:29 Mar 12, 2012
Jkt 226001
Weeks of March 12, 19, 26, April
2, 9, 16, 2012.
PLACE: Commissioners’ Conference
Room, 11555 Rockville Pike, Rockville,
Maryland.
STATUS: Public and closed.
DATE:
Week of March 12, 2012
There are no meetings scheduled for
the week of March 12, 2012.
Week of March 19, 2012—Tentative
There are no meetings scheduled for
the week of March 19, 2012.
Week of March 26, 2012—Tentative
Tuesday, March 27, 2012
9 a.m.—Briefing on License Renewal for
Research and Test Reactors (Public
Meeting) (Contact: Jessie
Quichocho, 301–415–0209).
This meeting will be webcast live at
the Web address—www.nrc.gov.
Week of April 2, 2012—Tentative
need this meeting notice or the
transcript or other information from the
public meetings in another format (e.g.
braille, large print), please notify Bill
Dosch, Chief, Work Life and Benefits
Branch, at 301–415–6200, TDD: 301–
415–2100, or by email at
william.dosch@nrc.gov. Determinations
on requests for reasonable
accommodation will be made on a caseby-case basis.
*
*
*
*
*
This notice is distributed
electronically to subscribers. If you no
longer wish to receive it, or would like
to be added to the distribution, please
contact the Office of the Secretary,
Washington, DC 20555 (301–415–1969),
or send an email to
darlene.wright@nrc.gov.
Dated: March 8, 2012.
Rochelle C. Bavol,
Policy Coordinator, Office of the Secretary.
[FR Doc. 2012–6148 Filed 3–9–12; 4:15 pm]
BILLING CODE 7590–01–P
Tuesday April 3, 2012
9:30 a.m.—Meeting with Organization of
Agreement States (OAS) and
Conference of Radiation Control
Program Directors (CRCPD) (Public
Meeting) (Contact: Cindy Flannery,
301–415–0223).
This meeting will be webcast live at
the Web address—www.nrc.gov.
NUCLEAR REGULATORY
COMMISSION
[Docket No. 70–7016; NRC–2009–0157]
Week of April 9, 2012—Tentative
General Electric-Hitachi Global Laser
Enrichment LLC, Commercial LaserBased Uranium Enrichment Facility,
Wilmington, North Carolina; NUREG–
2120
Tuesday, April 10, 2012
AGENCY:
9 a.m.—Briefing on the Final Report of
the Blue Ribbon Commission on
America’s Nuclear Future (Public
Meeting) (Contact: Alicia Mullins,
301–492–3351).
This meeting will be webcast live at
the Web address—www.nrc.gov.
SUMMARY:
Week of April 16, 2012—Tentative
There are no meetings scheduled for
the week of April 16, 2012.
*
*
*
*
*
* The schedule for Commission
meetings is subject to change on short
notice. To verify the status of meetings,
call (recording)—301–415–1292.
Contact person for more information:
Rochelle Bavol, 301–415–1651.
*
*
*
*
*
The NRC Commission Meeting
Schedule can be found on the Internet
at: https://www.nrc.gov/public-involve/
public-meetings/schedule.html.
*
*
*
*
*
The NRC provides reasonable
accommodation to individuals with
disabilities where appropriate. If you
need a reasonable accommodation to
participate in these public meetings, or
PO 00000
Frm 00115
Fmt 4703
Sfmt 4703
Nuclear Regulatory
Commission.
ACTION: Notice of availability of safety
evaluation report.
The Nuclear Regulatory
Commission (NRC or the Commission)
is considering the issuance of a license
to General Electric-Hitachi Global Laser
Enrichment LLC (GLE or the applicant)
to authorize construction of a laserbased uranium enrichment facility and
possession and use of byproduct
material, source material, and special
nuclear material (SNM). This proposed
facility is proposed to be located in
Wilmington, North Carolina. The NRC
prepared a Safety Evaluation Report
(SER) in support of this license
application.
ADDRESSES: Please refer to Docket ID
NRC–2009–0157 when contacting the
NRC about the availability of
information regarding this document.
You may access information related to
this document, which the NRC
possesses and is publicly-available,
using the following methods:
• Federal Rulemaking Web site: Go to
https://www.regulations.gov and search
for Docket ID NRC–2009–0157. Address
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 77, Number 49 (Tuesday, March 13, 2012)]
[Notices]
[Pages 14837-14838]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-5998]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Meeting
Notice
AGENCY: U.S. Nuclear Regulatory Commission.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: NRC will convene a meeting of the Advisory Committee on the
Medical Uses of Isotopes (ACMUI) on April 16-17, 2012. A sample of
agenda items to be discussed during the public session includes: (1)
Fundamental concepts in patient advocacy; (2) electronic signatures for
documents that are required to be signed in accordance with U.S.
Nuclear Regulatory Commission (NRC) regulations; (3) medical-related
events from fiscal year 2011; (4) an update on proposed regulatory
changes for Permanent Implant Brachytherapy programs; (5) the status of
the Commission Paper on data collection for Patient Release; (6) a
status update on 10 CFR Part 35 rulemaking; (7) medical use of radium-
223 chloride; (8) an update on strontium breakthrough with rubidium-82
generators from NRC and FDA perspectives; and (9) half-life activity as
a function of solar activity. The agenda is subject to change. The
current agenda and any updates will be available at https://www.nrc.gov/reading-rm/doc-collections/acmui/agenda or by emailing Ms. Sophie
Holiday at the contact information below.
Purpose: Discuss issues related to 10 CFR Part 35 Medical Use of
Byproduct Material.
Date and Time for Closed Session: April 16, 2012, from 8 a.m. to
10:45 a.m. This session will be closed so that ACMUI members can
prepare for an upcoming Commission briefing.
Date and Time for Open Sessions: April 16, 2012, from 10:45 a.m. to
5 p.m. and April 17, 2012, from 8 a.m. to 12:30 p.m.
Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two
White Flint North Building, Room T2-
[[Page 14838]]
B3, 11545 Rockville Pike, Rockville, Maryland 20852.
Public Participation: Any member of the public who wishes to
participate in the meeting in person or via phone should contact Ms.
Holiday using the information below. The meeting will also be webcast
live: https://www.nrc.gov/public-involve/public-meetings/webcast-live.html.
Contact Information: Sophie J. Holiday, email:
sophie.holiday@nrc.gov, telephone: (301) 415-7865.
Conduct of the Meeting
Leon S. Malmud, M.D., will chair the meeting. Dr. Malmud will
conduct the meeting in a manner that will facilitate the orderly
conduct of business. The following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a written statement should submit an
electronic copy to Ms. Holiday at the contact information listed above.
All submittals must be received by April 9, 2012, and must pertain to
the topic on the agenda for the meeting.
2. Questions and comments from members of the public will be
permitted during the meeting, at the discretion of the Chairman.
3. The draft transcript will be available on ACMUI's Web site
(https://www.nrc.gov/reading-rm/doc-collections/acmui/tr/) on or about
May 18, 2012. A meeting summary will be available on ACMUI's Web site
(https://www.nrc.gov/reading-rm/doc-collections/acmui/meeting-summaries/
) on or about May 29, 2012.
4. Persons who require special services, such as those for the
hearing impaired, should notify Ms. Holiday of their planned
attendance.
This meeting will be held in accordance with the Atomic Energy Act
of 1954, as amended (primarily Section 161a); the Federal Advisory
Committee Act (5 U.S.C. App); and the Commission's regulations in Title
10, U.S. Code of Federal Regulations, Part 7.
Dated: March 7, 2012.
Andrew L. Bates,
Advisory Committee Management Officer.
[FR Doc. 2012-5998 Filed 3-12-12; 8:45 am]
BILLING CODE 7590-01-P
